Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1008392
Abstract: Background Livedoid vasculopathy is a rare, chronic, and recurrent disease with limited effective treatments. Its etiopathogenesis remains incompletely understood. Baricitinib, a selective Janus kinase 1 and 2 inhibitor, has been used to treat rheumatoid arthritis… read more here.
Keywords: refractory livedoid; treatment refractory; baricitinib treatment; treatment ... See more keywords
Adalimumab in Treating Refractory Livedoid Vasculopathy
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10040549
Abstract: Livedoid vasculopathy is a chronic, recurrent skin disorder. It seriously affects the quality of patients’ life. However, the pathogenesis has not been fully identified yet. Here, this retrospective study describes the successful use of anti-TNF-α… read more here.
Keywords: treating refractory; adalimumab treating; refractory livedoid; livedoid vasculopathy ... See more keywords